{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:30:33Z","timestamp":1771673433827,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS)","doi-asserted-by":"publisher","award":["26450409"],"award-info":[{"award-number":["26450409"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.lfs.2016.01.047","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T03:45:47Z","timestamp":1454298347000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma"],"prefix":"10.1016","volume":"159","author":[{"given":"Shinya","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Saida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetomo","family":"Iwano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Uchide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2016.01.047_bb0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0195-5616(03)00002-0","article-title":"Hemangiosarcoma in dogs and cats","volume":"33","author":"Smith","year":"2003","journal-title":"Vet. Clin. North Am. Small Anim. Pract."},{"key":"10.1016\/j.lfs.2016.01.047_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcpa.2012.11.234","article-title":"Canine splenic haemangiosarcoma: influence of metastases, chemotherapy and growth pattern on post-splenectomy survival and expression of angiogenic factors","volume":"149","author":"Goritz","year":"2013","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.lfs.2016.01.047_bb0015","first-page":"1165","article-title":"Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial","volume":"1","author":"Vail","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.047_bb0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1139\/Y08-058","article-title":"The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy","volume":"86","author":"Bagnato","year":"2008","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.lfs.2016.01.047_bb0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1043-2760(98)00094-0","article-title":"Endothelins as autocrine regulators of tumor cell growth","volume":"9","author":"Bagnato","year":"1998","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2016.01.047_bb0030","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1073\/pnas.96.20.11496","article-title":"An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo","volume":"96","author":"Lahav","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2016.01.047_bb0035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2016.01.047_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tvjl.2015.03.024","article-title":"Big endothelin-1 as a tumour marker for canine haemangiosarcoma","volume":"204","author":"Fukumoto","year":"2015","journal-title":"Vet. J."},{"key":"10.1016\/j.lfs.2016.01.047_bb0045","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1158\/0008-5472.CAN-03-1069","article-title":"A role for endothelin-2 and its receptors in breast tumor cell invasion","volume":"64","author":"Grimshaw","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.047_bb0050","first-page":"385398","article-title":"Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence","volume":"2013","author":"Tamkus","year":"2013","journal-title":"ISRN Oncol."},{"key":"10.1016\/j.lfs.2016.01.047_bb0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2407-9-363","article-title":"Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes","volume":"9","author":"Kodama","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2016.01.047_bb0060","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.3171\/foc.2000.8.5.6","article-title":"Evaluation of big endothelin-1 concentrations in serum and ventricular cerebrospinal fluid after early surgical compared with nonsurgical management of ruptured intracranial aneurysms","volume":"8","author":"Gruber","year":"2000","journal-title":"Neurosurg. Focus."},{"key":"10.1016\/j.lfs.2016.01.047_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tvjl.2013.06.022","article-title":"Big-endothelin 1 (big ET-1) and homocysteine in the serum of dogs with chronic kidney disease","volume":"198","author":"Rossi","year":"2013","journal-title":"Vet. J."},{"key":"10.1016\/j.lfs.2016.01.047_bb0070","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.intimp.2008.03.023","article-title":"Serum big endothelin-1 levels in female patients with breast cancer","volume":"8","author":"Yildirim","year":"2008","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2016.01.047_bb0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cbpb.2004.05.008","article-title":"High altitude training of dogs results in elevated erythropoietin and endothelin-1 serum levels","volume":"138","author":"Glaus","year":"2004","journal-title":"Comp. Biochem. Physiol. A Mol. Integr. Physiol."},{"key":"10.1016\/j.lfs.2016.01.047_bb0080","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1292\/jvms.67.1155","article-title":"Elevated endothelin-1 expression in dogs with heartworm disease","volume":"67","author":"Uchide","year":"2005","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.lfs.2016.01.047_bb0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbrc.2013.08.020","article-title":"A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model","volume":"439","author":"Fukumoto","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2016.01.047_bb0090","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1210\/en.2006-1553","article-title":"Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively","volume":"148","author":"Mitsutake","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2016.01.047_bb0095","first-page":"663","article-title":"Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer","volume":"56","author":"Nelson","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.047_bb0100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-10-2340","article-title":"An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma","volume":"17","author":"Asundi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.047_bb0105","first-page":"1117","article-title":"Correlated expression levels of endothelin receptor B and plexin C1 in melanoma","volume":"5","author":"Kumasaka","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.047_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cardiores.2007.06.004","article-title":"The importance of endothelin-1 for vascular dysfunction in cardiovascular disease","volume":"76","author":"Bohm","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2016.01.047_bb0115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM199508103330607","article-title":"Endothelins","volume":"333","author":"Levin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2016.01.047_bb0120","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00005344-200000002-00002","article-title":"The endothelin family: an overview","volume":"35","author":"Masaki","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.lfs.2016.01.047_bb0125","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2016.01.047_bb0130","first-page":"35","article-title":"Methylation of the 5\u2032 CpG island of the endothelin B receptor gene is common in human prostate cancer","volume":"57","author":"Nelson","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2016.01.047_bb0135","first-page":"1","article-title":"Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review","author":"Peacock","year":"2015","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320516300467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320516300467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T17:22:17Z","timestamp":1537032137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320516300467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":27,"alternative-id":["S0024320516300467"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2016.01.047","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2016.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}